Amiel J L, Cukier J, Droz J P
J Urol (Paris). 1985;91(8):519-22.
Based on data obtained from a general review of treatment of infiltrating cancer of bladder, new therapeutic orientations are proposed in which chemotherapy occupies a privileged position as adjuvant treatment of surgical excision. Emphasis is placed on the frequency of bladder cancer and invasive tumors, as well as the high incidence of unsuccessful results due not to local recurrence but to metastases that do not respond to local and regional radiosurgical treatment. Objective results are obtained in approximately 50% of measurable metastases after combined Adriamycin and Cisplatin treatment. The efficacy of this chemotherapy suggests its prophylactic use to eradicate microscopic metastatic lesions remaining after local and regional therapy. If indications are well chosen, and not too heavy chemotherapy administered, then it is probable that as complementary treatment to surgical excision should improve efficacy of treatment of infiltrating cancer of bladder. The observation of necrosis of pulmonary metastases during chemotherapy provides justification for therapeutic orientation of this type.
基于对浸润性膀胱癌治疗的综合回顾所获得的数据，提出了新的治疗方向，其中化疗作为手术切除的辅助治疗占据了优先地位。重点关注膀胱癌和浸润性肿瘤的发生率，以及由于转移而非局部复发导致治疗结果不佳的高发生率，这些转移对局部和区域放射外科治疗无反应。联合使用阿霉素和顺铂治疗后，约50%的可测量转移灶可获得客观疗效。这种化疗的疗效表明可预防性使用以根除局部和区域治疗后残留的微小转移病灶。如果适应症选择得当，且化疗剂量不过大，那么作为手术切除的补充治疗有可能提高浸润性膀胱癌的治疗效果。化疗期间观察到肺转移灶坏死为这种治疗方向提供了依据。
